The Middle East & Africa Prefilled Syringes Market size is estimated to value USD 2.41 billion by 2027 from USD 0.45 billion in 2022, growing at a CAGR of 40% from 2022 to 2027.
A single-dose vaccination package with a needle is known as a prefilled syringe. Metal or glass syringes were previously used, but today plastic and disposable syringes are more common, preserving the needle and preventing it from reusing (the prefilled disposable systems). Prefilled syringes make injections simple, accurate, and safe for both patients and clinicians.
Prefilled syringes have emerged as one of the fastest increasing choices for unit dosage medicine as the pharmaceutical industry explores new and more convenient drug delivery methods. As a result, prefilled syringes have been utilized in various therapeutic disciplines, in addition to vaccinations, blood stimulants, and pharmaceutical proteins.
The healthcare sector has seen chronic illnesses such as cardiovascular, cancer, respiratory, and diabetes, especially in developing nations, owing to lifestyle changes and a lack of preventative care possibilities. Therefore, its sole purpose is to increase market demand for prefilled syringes.
Prefilled syringes are most commonly used to treat chronic illnesses that need patients to self-administer medications, such as heart disease, diabetes, and autoimmune diseases. As a result, the rising incidence and prevalence of chronic and lifestyle illnesses throughout the region is a significant driver driving the prefilled syringes market forward in the MEA region. Furthermore, due to the ease and safety associated with their usage, there is an increasing demand for self-injection devices.
Certain difficulties, such as medication interaction with primary packaging, may impact the growth of the MEA prefilled syringes market. In addition, the response to plastic impacts medication quality, which is stifling market expansion. Various product recalls owing to contaminants or syringe leaks are expected to limit market growth during the projected period.
This research report on the Middle East and Africa prefilled syringes market has been segmented and sub-segmented into the following categories:
By Distribution Channel:
The MEA is anticipated to account for a considerable share in the global prefilled syringes market during the forecast period. The market for prefilled syringes in the Middle East and Africa is primarily driven by key players' initiatives to build up manufacturing facilities in emerging and established regions. In addition, the market for prefilled syringes in the Middle East and Africa is anticipated to rise due to factors such as a growth in the number of chronic illnesses and infectious diseases and greater use of injectable medicines. However, due to lesser awareness of new goods and poor market penetration, the Middle East and Africa regions are expected to moderate this industry's development.
The South African prefilled syringes market is expected to witness a considerable share in the prefilled syringes market during the forecast period; this is due to the rise in the number of chronic diseases, including diabetes and rheumatoid arthritis, which is expected to increase the demand for chronic drug treatment at a precise dose level.
On the other hand, countries such as UAE and Saudi Arabia are more projected to contribute to the MEA regional market growth. Leading market players are frequently observed putting effective tactics to thrive in their areas and get maximum traction in their businesses. To expand its client base, key players provide a wide range of refillable syringes to a large number of pharmaceutical manufacturing businesses and place a significant emphasis on growing its distribution network through a strategic partnership with numerous research institutions.
KEY MARKET PARTICIPANTS:
A few of the leading companies in the MEA prefilled syringes market profiled in this report are Becton Dickinson and Company, Gerresheimer AG, SCHOTT AG, West Pharmaceutical Services, Inc., Ompi, Catalent, Inc., Weigao Group, Vetter Pharma International GmbH, Nipro Corporation & MedPro Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com